Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus

Sandra P. Frizelle; Jeff B Rubins; Joan X. Zhou; David T. Curiel; Robert A Kratzke

doi:10.1038/sj.cgt.7700241

Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus

Sandra P. Frizelle, Jeff B Rubins, Joan X. Zhou, David T. Curiel, Robert A Kratzke

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.

Original language	English (US)
Pages (from-to)	1421-1425
Number of pages	5
Journal	Cancer gene therapy
Volume	7
Issue number	11
DOIs	https://doi.org/10.1038/sj.cgt.7700241
State	Published - 2000

Bibliographical note

Funding Information:
The authors thank Alexander Shar, Ryan Dick, and Jacob Liston for their assistance with animal care. This study was supported by grants from the Minnesota Medical Foundation (R.A.K), the Research Service of the Department of Veterans Affairs (R.A.K), and the National Institutes of Health (D.T.C.) (R01 CA72532; R01 CA74242).

Keywords

Cell cycle
Gene therapy
Mesothelioma
Tumor suppressor
p16(INK4a)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/sj.cgt.7700241

Find It

Find It at U of M Libraries

Cite this

@article{a7ebdf131d5a4bc1a552d051223df19e,

title = "Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus",

abstract = "The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.",

keywords = "Cell cycle, Gene therapy, Mesothelioma, Tumor suppressor, p16(INK4a)",

author = "Frizelle, {Sandra P.} and Rubins, {Jeff B} and Zhou, {Joan X.} and Curiel, {David T.} and Kratzke, {Robert A}",

note = "Funding Information: The authors thank Alexander Shar, Ryan Dick, and Jacob Liston for their assistance with animal care. This study was supported by grants from the Minnesota Medical Foundation (R.A.K), the Research Service of the Department of Veterans Affairs (R.A.K), and the National Institutes of Health (D.T.C.) (R01 CA72532; R01 CA74242).",

year = "2000",

doi = "10.1038/sj.cgt.7700241",

language = "English (US)",

volume = "7",

pages = "1421--1425",

journal = "Cancer gene therapy",

issn = "0929-1903",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus

AU - Frizelle, Sandra P.

AU - Rubins, Jeff B

AU - Zhou, Joan X.

AU - Curiel, David T.

AU - Kratzke, Robert A

N1 - Funding Information: The authors thank Alexander Shar, Ryan Dick, and Jacob Liston for their assistance with animal care. This study was supported by grants from the Minnesota Medical Foundation (R.A.K), the Research Service of the Department of Veterans Affairs (R.A.K), and the National Institutes of Health (D.T.C.) (R01 CA72532; R01 CA74242).

PY - 2000

Y1 - 2000

N2 - The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.

AB - The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.

KW - Cell cycle

KW - Gene therapy

KW - Mesothelioma

KW - Tumor suppressor

KW - p16(INK4a)

UR - http://www.scopus.com/inward/record.url?scp=0033664624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033664624&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700241

DO - 10.1038/sj.cgt.7700241

M3 - Article

C2 - 11129284

AN - SCOPUS:0033664624

SN - 0929-1903

VL - 7

SP - 1421

EP - 1425

JO - Cancer gene therapy

JF - Cancer gene therapy

IS - 11

ER -

Gene therapy of established mesothelioma xenografts with recombinant p16(INK4a) adenovirus

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this